Difference Between Left-Sided and Right-Sided Colorectal Cancer: A Focused Review of Literature
Open accessThe DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index.
Abstract
Colorectal cancer is the third most common cancer worldwide with a high mortality rate at the advanced stages. However, colorectal cancer is not a single type of tumor; its pathogenesis depends on the anatomical location of the tumor and differs between right side and left side of the colon. Tumors in the proximal colon (right side) and distal colon (left side) exhibit different molecular characteristics and histology. In the right-sided tumors, mutations in the DNA mismatch repair pathway are commonly observed; and these tumors generally have a flat histology. In the left-sided tumors, chromosomal instability pathway-related mutations, such as KRAS, APC, PIK3CA, p53 mutations are observed and these tumors demonstrate polypoid-like morphology. Therapy responses are totally different between these tumor entities. Left-sided colorectal cancer (LCRC) patients benefit more from adjuvant chemotherapies such as 5-fluorouracil (5-FU)-based regimes, and targeted therapies such as anti- epidermal growth factor receptor (EGFR) therapy, and have a better prognosis. Right-sided colorectal cancer (RCRC) patients do not respond well to conventional chemotherapies, but demonstrate more promising results with immunotherapies because these tumors have high antigenic load. For the development of effective therapy regimes and better treatment options, it is essential to evaluate right-sided and left-sided tumors as separate entities, and design the therapy regime considering the differences between these tumors. Gastroenterol Res. 2018;11(4):264-273 doi: https://doi.org/10.14740/gr1062w
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Right-sided tumors more commonly exhibit DNA mismatch repair deficiencies, while left-sided tumors often have mutations in KRAS, APC, PIK3CA, and p53 [30].”
From Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer (2024) · cites this paper as [30]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015) · International Journal of Cancer · doi:10.1002/ijc.29210 · Cited by 28,766
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838 · cited 1×
“highly use these regulators as an anti-tumor immune response [82, 83].”
BackgroundA genetic model for colorectal tumorigenesis
Fearon, E. R., & Vogelstein, B. (1990) · Cell · doi:10.1016/0092-8674(90)90186-i · Cited by 12,132 · cited 1×
“In this model, carcinogenesis begins with the inactivation or deletion of adenomatous polyposis coli (APC) tumor suppressor gene, followed by the activation of Kirsten ras homolog (KRAS) oncogene, the inactivation of p53 tumor suppressor gene and other mutations [47, 48].”
MethodPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945 · cited 1×
“Metastatic melanoma is one of the tumors with high immunogenic load and melanoma patients are highly benefiting from anti-CTLA-4 and anti-PD-1 therapies [87, 88].”
BackgroundGenetic Alterations during Colorectal-Tumor Development
Vogelstein, B., Fearon, E. R., Hamilton, S. R., Kern, S. E., Preisinger, A. C., Leppert, M., Smits, A. M. M., & Bos, J. L. (1988) · New England Journal of Medicine · doi:10.1056/nejm198809013190901 · Cited by 6,728 · cited 1×
“In this model, carcinogenesis begins with the inactivation or deletion of adenomatous polyposis coli (APC) tumor suppressor gene, followed by the activation of Kirsten ras homolog (KRAS) oncogene, the inactivation of p53 tumor suppressor gene and other mutations [47, 48].”
MethodType, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516 · cited 4×
“Presence of T cells in these tumors is associated with better prognosis and less frequent metastasis [12, 13, 24].”
BackgroundInfluentialImmune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229 · cited 1×
“Interestingly, tumor infiltrating lymphocytes express high level of PD-L1, which is thought to be a result of chronic stimulation because of the neoantigen load [86].”
Background
Cited by
Treatment of Metastatic Colorectal Cancer: ASCO Guideline
Morris, V. K., Kennedy, E. B., Baxter, N. N., Benson, A. B., Cercek, A., Cho, M., Ciombor, K. K., Cremolini, C., Davis, A., Deming, D. A., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.01690 · Cited by 682
“fluorouracil (FU)–based chemotherapy, and more recently, targeted therapies have been developed for specific molecular subtypes and primary tumor sidedness.(6) This guideline provides a review of the evidence for areas of uncertainty in the treatment of mCRC, including indications for targeted therapy, and treatment o…”
BackgroundPrognostic and Predictive Molecular Biomarkers for Colorectal Cancer: Updates and Challenges
Koncina, E., Haan, S., Rauh, S., & Letellier, E. (2020) · Cancers · doi:10.3390/cancers12020319 · Cited by 259
“Additionally, the two parts of the colon have different blood supplies, distinct microbiome populations and are associated with different biological features [80].”
BackgroundInfluentialSmoking and Colorectal Cancer Risk, Overall and by Molecular Subtypes: A Meta-Analysis
Botteri, E., Borroni, E., Sloan, E. K., Bagnardi, V., Bosetti, C., Peveri, G., Santucci, C., Specchia, C., van den Brandt, P., Gallus, S., et al. (2020) · American Journal of Gastroenterology · doi:10.14309/ajg.0000000000000803 · Cited by 229
“MSI-high CRC occurs in the proximal part of the colon and with increased frequency in women (34).”
BackgroundSwain, C. K. (2024) · Discover Environment · doi:10.1007/s44274-024-00030-8 · Cited by 165
“Growing awareness of ever-expanding industrialization as well as intensive agricultural soil use and their influence on the content of heavy metals in the soil necessitates the appropriate evaluation as well as determination of their ecological risk [54, 55].”
The microbial landscape of colorectal cancer
White, M. T., & Sears, C. L. (2024) · Nature Reviews Microbiology · doi:10.1038/s41579-023-00973-4 · Cited by 161
“The vast majority of CRCs begin as precursor lesions called polyps, formed by clonal colonic epithelial cell expansion 87 .”
InfluentialGenome-Wide Sex and Gender Differences in Cancer
Lopes-Ramos, C. M., Quackenbush, J., & DeMeo, D. L. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.597788 · Cited by 163
“Compared to distal colon, patients with proximal colon cancer are predominantly females (174).”
BackgroundPiccinno (2025) · doi:10.1038/s41591-025-03693-9 · Cited by 133
“…based on primary tumor location in two main classes: right-sided CRC, namely originating from the cecum, ascending colon, hepatic flexure and transverse colon; and left-sided CRC, namely originating from the splenic flexure, descending or sigmoid colon, rectosigmoid junction and rectum 57 .”
Bylsma, L. C., Gillezeau, C., Garawin, T. A., Kelsh, M. A., Fryzek, J. P., Sangaré, L., & Lowe, K. A. (2020) · Cancer Medicine · doi:10.1002/cam4.2747 · Cited by 133
Update on Targeted Therapy and Immunotherapy for Metastatic Colorectal Cancer
Underwood, P. W., Ruff, S. M., & Pawlik, T. M. (2024) · Cells · doi:10.3390/cells13030245 · Cited by 130
“Right-sided tumors more commonly exhibit DNA mismatch repair deficiencies, while left-sided tumors often have mutations in KRAS, APC, PIK3CA, and p53 [30].”
BackgroundThe Role of p53 Dysfunction in Colorectal Cancer and Its Implication for Therapy
Michel, M., Kaps, L., Maderer, A., Galle, P. R., & Moehler, M. (2021) · Cancers · doi:10.3390/cancers13102296 · Cited by 108
“Mutations of the DNA mismatch repair system are frequently observed together with changes to oncogenes and/or tumor suppressor genes such as KRAS, APC, PIK3CA and TP53 [22].”
BackgroundSun, X., He, L., Liu, H., Thorne, R. F., Zeng, T., Liu, L., Zhang, B., He, M., Huang, Y., Li, M., et al. (2023) · Cell Metabolism · doi:10.1016/j.cmet.2023.07.005 · Cited by 109
Degree and site of chromosomal instability define its oncogenic potential
Hoevenaar, W. H. M., Janssen, A., Quirindongo, A. I., Ma, H., Klaasen, S. J., Teixeira, A., van Gerwen, B., Lansu, N. R., Morsink, F. H. M., Offerhaus, G. J. A., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15279-9 · Cited by 111
“Furthermore, as in human FAP, colonic tumors of CiMKi;ApcMin/+ mice are predominantly located in the distal colon and are aneuploid and karyotypically heterogeneous (Baran et al., 2018).”
BackgroundThe clinical relevance of gene expression based prognostic signatures in colorectal cancer
Ahluwalia, P. K., Kolhe, R. B., & Gahlay, G. K. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188513 · Cited by 116
Petrowsky, H., Linecker, M., Raptis, D. A., Kuemmerli, C., Fritsch, R., Kırımker, O. E., Balcı, D., Ratti, F., Aldrighetti, L. A., Voskanyan, S. E., et al. (2020) · Annals of Surgery · doi:10.1097/sla.0000000000004330 · Cited by 103
“98% 457 (92) 93% 317 (67) 88% 139 (31) 310 (69) 63% 40 (13) 83 (26) 97 (30) 88 (28) 11 (3)”
Alves, N. D. O., Dalmasso, G., Nikitina, D., Vaysse, A., Ruez, R., Ledoux, L., Pédron, T., Bergsten, E., Boulard, O., Autier, L., et al. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2320291 · Cited by 106
“It has been established that patients with right-sided CRC exhibit a worse prognosis and differences in their tumor-associated biofilms 2,18 and lipid metabolism when compared to left-sided CRC. 22 However, it remains unclear whether the tumor-associated microbiota may influence the metabolic…”
BackgroundCaspi, M., Wittenstein, A., Kazelnik, M., Shor-Nareznoy, Y., & Rosin‐Arbesfeld, R. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.12.010 · Cited by 96
Genetic and epigenetic dependencies in colorectal cancer development
Parmar, S., & Easwaran, H. (2022) · Gastroenterology report · doi:10.1093/gastro/goac035 · Cited by 99
“A hallmark of 70%–80% of CIN cases is loss of the tumor suppressor and Wnt pathway negative regulator APC, which occurs by sporadic mutation in one allele of APC followed by loss of the other APC allele due to flaws in chromosome segregation [16, 17].”
BackgroundFilip, S., Vymetalkova, V. P., Petera, J., Vodičková, Ľ., Kubeček, O., John, S., Čečka, F., Krupova, M., Manethová, M., Červená, K., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21155255 · Cited by 97
Lang, H., Baumgart, J., Heinrich, S., Tripke, V., Passalaqua, M., Maderer, A., Galle, P. R., Roth, W., Kloth, M. T., & Moehler, M. H. (2019) · Annals of Surgery · doi:10.1097/sla.0000000000003527 · Cited by 85
“The most prominent and frequently analyzed mutations affect the RAS/RAF-pathway (KRAS, NRAS, BRAF) as well as TP53 and PIK3CA.19,20 Brudvik et al21 refined the traditional Fong score16 by a modified clinical risk score (m-CS) just including the lymph node status of the primary and the size of the largest metastases, b…”
BackgroundOncogenic BRAF, unrestrained by TGFβ-receptor signalling, drives right-sided colonic tumorigenesis
Leach, J. D. G., Vlahov, N., Tsantoulis, P., Ridgway, R. A., Flanagan, D. J., Gilroy, K., Sphyris, N., Vázquez, E. G., Vincent, D. F., Faller, W. J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23717-5 · Cited by 82
Time trends of colorectal cancer incidence and associated lifestyle factors in South Korea
Khil, H., Kim, S., Hong, S., Gil, H., Cheon, E., Lee, D. H., Kim, Y. A., & Keum, N. (2021) · Scientific Reports · doi:10.1038/s41598-021-81877-2 · Cited by 90
Mechanisms and Strategies to Overcome Drug Resistance in Colorectal Cancer
Haynes, J., & Manogaran, P. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051988 · Cited by 82
“Within the colon, most tumors develop in the distal colon (~70%), which includes the descending colon, sigmoid colon, and distal one-third of the transverse colon [6].”
Association Between the Sulfur Microbial Diet and Risk of Colorectal Cancer
Wang, Y., Nguyen, L. H., Mehta, R. S., Song, M., Huttenhower, C., & Chan, A. T. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.34308 · Cited by 89
The Evolving Biomarker Landscape for Treatment Selection in Metastatic Colorectal Cancer
Taieb, J., Jung, A., Sartore-Bianchi, A., Peeters, M., Seligmann, J., Zaanan, A., Burdon, P., Montagut, C., & Laurent-Puig, P. (2019) · Drugs · doi:10.1007/s40265-019-01165-2 · Cited by 76
Guo, J., Chen, D., Deng, S.-H., Huang, J.-R., Song, J., Li, X.-Y., Cui, B., & Liu, Y. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-021-03076-2 · Cited by 85
Therapeutic Targeting of the Colorectal Tumor Stroma
Fridman, W. H., Miller, I. S., Sautès‐Fridman, C., & Byrne, A. T. (2019) · Gastroenterology · doi:10.1053/j.gastro.2019.09.045 · Cited by 79
Gupta, R., Othman, T., Chen, C., Sandhu, J., Ouyang, C., & Fakih, M. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0441 · Cited by 70
“This is consistent with prior studies that have shown that left-sided colon cancers tend to have an increased chromosomal instability high tumor (CIN high) compared with right-sided tumors [34].”
ResultMolecular features and gene expression signature of metastatic colorectal cancer (Review)
Poturnajova, M., Furielova, T., Balintova, S., Schmidtova, S., Kučerová, L., & Matúšková, M. (2021) · Oncology Reports · doi:10.3892/or.2021.7961 · Cited by 76
De, S., Paul, S., Manna, A., Majumder, C., Pal, K., Casarcia, N., Mondal, A., Banerjee, S., Nelson, V. K., Ghosh, S., et al. (2023) · Cancers · doi:10.3390/cancers15030993 · Cited by 76
“However, cetuximab was inactive in CRCs carrying the RAS (KRAS) mutation.”
BackgroundInfluentialAnania, G., Davies, J., Bagolini, F., Vettoretto, N., Randolph, J., Cirocchi, R., & Donini, A. (2021) · Techniques in Coloproctology · doi:10.1007/s10151-021-02471-2 · Cited by 68
Keratin intermediate filaments in the colon: guardians of epithelial homeostasis
Polari, L., Alam, C. M., Nyström, J. H., Heikkilä, T. R. H., Tayyab, M., Baghestani, S., & Toivola, D. M. (2020) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2020.105878 · Cited by 67
Lawler, T., Parlato, L., & Andersen, S. W. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1349572 · Cited by 69
“Notably, aggressive histological subtypes are overrepresented in the proximal colon (104), and consequently the association with early-onset CRC is not explained by differences in tumor location.”
BackgroundRecent Updates on the Significance of KRAS Mutations in Colorectal Cancer Biology
László, L., Kurilla, A., Takács, T., Kudlik, G., Koprivanacz, K., Buday, L., & Vas, V. (2021) · Cells · doi:10.3390/cells10030667 · Cited by 58
“The observation that right-sided CRC has a worse prognosis compared to the left-sided tumours has been described earlier, and KRAS and BRAF mutations have recently also been established as negative prognostic cancer markers [76,77].”
BackgroundNanoparticles: Attractive tools to treat colorectal cancer
Younis, N. K., Roumieh, R., Bassil, E. P., Ghoubaira, J. A., Kobeissy, F. H., & Eid, A. H. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.08.006 · Cited by 63
Molecular Pathogenesis and Classification of Colorectal Carcinoma
Kasi, A., Handa, S., Bhatti, S. A., Umar, S., Bansal, A. K., & Sun, W. (2020) · Current Colorectal Cancer Reports · doi:10.1007/s11888-020-00458-z · Cited by 79
Gharib, E., & Robichaud, G. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25179463 · Cited by 64
Russo, V., Lallo, E., Munnia, A., Spedicato, M., Messerini, L., D’Aurizio, R., Ceroni, E. G., Brunelli, G., Galvano, A., Russo, A., et al. (2022) · Cancers · doi:10.3390/cancers14164012 · Cited by 63
Sex Differences in Colorectal Cancer: Epidemiology, Risk Factors, and Clinical Outcomes
Tsokkou, S., Konstantinidis, I. K., Papakonstantinou, M., Chatzikomnitsa, P., Liampou, E., Toutziari, E., Giakoustidis, D. E., Bangeas, P., Papadopoulos, V. N., & Giakoustidis, A. E. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14155539 · Cited by 51
“The Cancer Genome Atlas (TCGA) study confirms the model and proposes various mutations, including APC , TP53 , KRAS , PIK3CA , FBXW7 , SMAD4 , TCF7L2 , and NRAS as being the most frequently mutated genes in CIN tumors [20,22].”
Vekić, J., Zeljković, A., Stefanović, A., Giglio, R. V., Ciaccio, M., & Rizzo, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222212409 · Cited by 56
“In the study of Siddiqui and co-workers [81], patients with poorly controlled T2DM had more right-sided tumors, which usually comprise a poorer prognosis [82], more advanced forms of the disease, as well as shorter survival.”
BackgroundKneis, B., Wirtz, S. J., Weber, K., Denz, A., Gittler, M. M., Geppert, C. I., Brunner, M., Krautz, C., Siebenhüner, A. R., Schierwagen, R., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043265 · Cited by 57
“In particular, RSCC presents with microsatellite instability, BRAF mutations, high immunogenicity and a worse prognosis [9,10].”
BackgroundscRNA-seq of colorectal cancer shows regional immune atlas with the function of CD20+ B cells
Ji, L., Fu, G., Huang, M., Kao, X., Zhu, J., Dai, Z., Chen, Y., Li, H., Zhou, J., Chu, X., et al. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.216664 · Cited by 53
Kaviarasan, V., Das, A., Deka, D., Saha, B., Banerjee, A., Sharma, N. R., Duttaroy, A. K., & Pathak, S. (2024) · International Journal of Colorectal Disease · doi:10.1007/s00384-024-04790-w · Cited by 53
Colorectal Cancer and Probiotics: Are Bugs Really Drugs?
Lamichhane, P., Maiolini, M., Alnafoosi, O., Hussein, S., Alnafoosi, H., Umbela, S., Richardson, T., Alla, N., Lamichhane, N., Subhadra, B., et al. (2020) · Cancers · doi:10.3390/cancers12051162 · Cited by 50
“These tumors commonly use checkpoint regulators to remain alive and avoid the immune system; thus, checkpoint inhibitor immunotherapies such as pembrolizumab (a programmed death 1 inhibitor) have been shown to be efficacious [7].”
BackgroundEpidemiology of Mucinous Adenocarcinomas
Benesch, M. G. K., & Mathieson, A. (2020) · Cancers · doi:10.3390/cancers12113193 · Cited by 46
“These cancers have a tendency towards the right colon, which classically does not present symptoms until late in the disease state relative to left-sided cancers [19].”
BackgroundRacial and Ethnic Disparities in Colorectal Cancer Screening and Outcomes
McLeod, M. R., Galoosian, A., & May, F. P. (2022) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2022.02.003 · Cited by 46
Interaction between microbiota and immunity and its implication in colorectal cancer
Xing, C., Du, Y., Duan, T., Nim, K., Chu, J., Wang, H. Y., & Wang, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.963819 · Cited by 51
Qi, L., Chen, J., Zhou, B., Xu, K., Wang, K., Fang, Z., Shao, Y., Yuan, Y., Zheng, S. S., & Hu, W. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03630-x · Cited by 51
Association Between Thyroid Disorders and Colorectal Cancer Risk in Adult Patients in Taiwan
L’Heureux, A., Wieland, D. R., Weng, C., Chen, Y.-H., Lin, C., Lin, T., & Weng, C. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.3755 · Cited by 48
Role of AI and digital pathology for colorectal immuno-oncology
Bilal, M., Nimir, M., Snead, D. R. J., Taylor, G. S., & Rajpoot, N. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01986-1 · Cited by 54
“They are predominantly located in the right side of the colon, are less likely to metastasise and are less sensitive to 5-fl uorocil-based chemotherapy used for fi rst-line therapy of CRC [26, 27].”
BackgroundCiepiela, I., Szczepaniak, M., Ciepiela, P., Hińcza, K., Kopczyński, J., Macek, P., Kubicka, K., Chrapek, M., Tyka, M., Góźdź, S. S., et al. (2024) · Scientific Reports · doi:10.1038/s41598-024-55139-w · Cited by 59
“Consistent with previous data, the present results indicate that tumors located on the left side are more frequent among men and are associated with TP53 gene mutations and liver metastases 15,16 .”
Forsberg, A. M., Widman, L., Bottai, M., Ekbom, A., & Hultcrantz, R. W. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.06.010 · Cited by 40
Acuña-Villaorduña, A., Lin, J., Kim, M., & Goel, S. (2021) · Cancer Medicine · doi:10.1002/cam4.3811 · Cited by 43
Sun, L., Huang, S., Li, D., Ye, M., Wang, Y., & Wu, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.754881 · Cited by 41
Vodicka, P., Andera, L., Opattova, A., & Vodickova, L. (2021) · Cancers · doi:10.3390/cancers13030479 · Cited by 39
“Regarding CRC, a recent review reported that mutations in TP53, KRAS, APC, and PIK3CA, occuring in left-sided tumors, demonstrate polypoid-like morphology and are associated with a chromosomal instability pathway [76,77].”
BackgroundWooldrage, K., Robbins, E. C., Duffy, S. W., & Cross, A. J. (2024) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(24)00190-0 · Cited by 38
Messaritakis, I., Vogiatzoglou, K., Tsantaki, K., Ntretaki, A., Sfakianaki, M., Koulouridi, A., Tsiaoussis, J., Mavroudis, D., & Souglakos, J. (2020) · Cancers · doi:10.3390/cancers12041058 · Cited by 41
“The authors mentioned that right-sided tumors usually respond only to immunotherapies due to their high antigenic load [39]; however, as addressed by others, despite no benefit in OS has been demonstrated, available data can endorse the use of an anti-epidermal growth factor receptor (anti-EGFR) treatment in right-sid…”
BackgroundTanaka, A., Ogawa, M., Zhou, Y., Namba, K., Hendrickson, R. C., Miele, M. M., Li, Z., Klimstra, D. S., Buckley, P. G., Gulcher, J. R., et al. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.113810 · Cited by 41
Zhou, Q., Lei, L., Cheng, J., Chen, J., Du, Y., Zhang, X., Li, Q., Li, C., Deng, H., Wong, C. C., et al. (2024) · Gut · doi:10.1136/gutjnl-2024-332193 · Cited by 40
Mao, R., Li, K., Cai, J., Luo, S., Turner, M. C., Blazer, D. G., & Zhao, H. (2019) · Annals of Surgery · doi:10.1097/sla.0000000000003562 · Cited by 36
Wu, M., Kim, Y. S., Ryu, H.-S., Choi, S. C., Kim, K. Y., Park, W. C., Kim, M. S., Myung, J. Y., Choi, H. S., Kim, E. J., et al. (2019) · Pathology - Research and Practice · doi:10.1016/j.prp.2019.152791 · Cited by 36
Sumransub, N., Vantanasiri, K., Prakash, A., & Lou, E. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.05.001 · Cited by 36
Saliba, J., Coutaud, B., Makhani, K., Roth, N. E., Jackson, J., Park, J. Y., Gagnon, N., Costa, P., Jeyakumar, T., Bury, M., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02192-2 · Cited by 38
“Differences between left and right tumors are well established, with left tumors being less immunogenic compared to right tumors which are highly infiltrated by T cells [61].”
BackgroundWu, J., Li, H., Xie, H., Wu, X., & Lan, P. (2019) · Carcinogenesis · doi:10.1093/carcin/bgy138 · Cited by 42
Recent advances and challenges in colorectal cancer: From molecular research to treatment
Qi, G., Zhao, R., Gao, C., Ma, Z., Wang, S., & Xu, J. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i21.106964 · Cited by 48
“…often manifests as sessile serrated adenomas, which are typically detected at later stages and are characterized by poor differentiation, high cellular atypia, frequent mucinous carcinoma, signet-ring cell carcinoma, undifferentiated carcinoma, and strong invasive and metastatic capabilities[36].”
Mao, Y., Wang, X., Xi, L., Dong, M., Song, P. K., Miao, J., Lu, C., Sun, S., Li, Q., Yu, C., et al. (2023) · International Journal of Surgery · doi:10.1097/js9.0000000000000483 · Cited by 38
“Patients with LCC benefit more from chemotherapy and targeted therapy and also experienced a better prognosis, while patients with RCC showed more promising results in immunotherapy([29]).”
BackgroundSaleh, R., Nair, V. S., Toor, S. M., Taha, R. Z., Murshed, K., Al‐Dhaheri, M., Khawar, M., Petkar, M. A., Nada, M. A., Al‐Ejeh, F., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001294 · Cited by 38
“16 17 18 19 Furthermore, increased number of intraepithelial CD8 + TILs has been associated with prolonged disease-specific survival (DSS) in patients with CRC. 20 IS of colon cancer, a trademark clinical measure based on the quantification of CD3 + and CD8 + T cells in the center of tumor (CT) and…”
Dysfunctional tumor-infiltrating Vδ1 + T lymphocytes in microsatellite-stable colorectal cancer
Stary, V., Pandey, R. V., List, J., Kleißl, L., Deckert, F., Kabiljo, J., Laengle, J., Gerakopoulos, V., Oehler, R., Watzke, L., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-51025-1 · Cited by 34
“The anatomical site is known to be of relevance for the microbiome, mutational status and metastatic spread 66 , factors that could possibly in fl uence the γδ T cells phenotype.”
DNA repair-dependent immunogenic liabilities in colorectal cancer: opportunities from errors
Amodio, V., Vitiello, P. P., Bardelli, A., & Germano, G. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02848-8 · Cited by 35
“There is evidence that the histology and molecular and immunological landscapes of CRCs arising on the right or left side of the colon are distinct [6].”
Identifying potential DNA methylation markers in early-stage colorectal Cancer
Zhang, X., Wan, S., Yu, Y., Ruan, W., Wang, H., Xu, L., Wang, C., Chen, S., Cao, T., Peng, Q., et al. (2020) · Genomics · doi:10.1016/j.ygeno.2020.06.007 · Cited by 33
The Comparison of Fecal Microbiota in Left-Side and Right-Side Human Colorectal Cancer
Miyake, T., Mori, H., Yasukawa, D., Hexun, Z., Maehira, H., Ueki, T., Kojima, M., Kaida, S., Iida, H., Shimizu, T., et al. (2021) · European Surgical Research · doi:10.1159/000516922 · Cited by 40
Loi, E., Zavattari, C., Tommasi, A., Moi, L., Canale, M., Pò, A., Sabato, C., Vega-Benedetti, A. F., Ziranu, P., Puzzoni, M., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-01738-1 · Cited by 33
Anti-EGFR Therapy in Metastatic Colorectal Cancer: Identifying, Tracking, and Overcoming Resistance
Leite, L. F., Noronha, M. M., de Menezes, J. S. A., da Conceição, L. D., Almeida, L. F. C., Cappellaro, A. P., Belotto, M., Biachi de Castria, T., Peixoto, R. D., & Megid, T. B. C. (2025) · Cancers · doi:10.3390/cancers17172804 · Cited by 32
“Tumors with BRAF V600E mutations and without microsatellite instability should be treated with FOLFOX, encorafenib, and cetuximab according to the recently published BREAKWATER trial [51].”
Fei, F., Li, C., Cao, Y., Liu, K., Du, J., Gu, Y., Wang, X., Li, Y., & Zhang, S. (2019) · Journal of Cancer · doi:10.7150/jca.29397 · Cited by 34
“Ascending colon cancer exhibits different histological and molecular characteristics compared with the left-side colon cancer [19].”
BackgroundClinicopathological differences and correlations between right and left colon cancer
Kalantzis, I. G., Nonni, A., Pavlakis, K., Delicha, E.-M., Miltiadou, K., Kosmas, C., Ziras, N., Gkoumas, K., & Gakiopoulou, H. (2020) · World Journal of Clinical Cases · doi:10.12998/wjcc.v8.i8.1424 · Cited by 36
Differences in the On- and Off-Tumor Microbiota between Right- and Left-Sided Colorectal Cancer
Phipps, O., Quraishi, M. N., Dickson, E. A., Steed, H., Kumar, A., Acheson, A. G., Beggs, A. D., Brookes, M., & Al-Hassi, H. O. (2021) · Microorganisms · doi:10.3390/microorganisms9051108 · Cited by 41
“Along with patients with right-sided colorectal cancer developing symptoms later, this may also explain why right-sided tumors tend to be more advanced and larger compared to left-sided tumors, as the right colonic microbiota is primed to support colorectal cancer progression [1].”
BackgroundThe gastrointestinal microbiota in colorectal cancer cell migration and invasion
Henstra, C., van Praagh, J., Olinga, P., & Nagelkerke, A. (2021) · Clinical & Experimental Metastasis · doi:10.1007/s10585-021-10130-x · Cited by 34
Early Onset Colorectal Cancer: Molecular Underpinnings Accelerating Occurrence
Zinkeng, A., Taylor, F. L., Cheong, S. H., Song, H., & Merchant, J. L. (2024) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2024.101425 · Cited by 35
“63,64 67 One report also suggests that patients with EO-CRC also present with higher rates of second primary malignancies in the initial 6 – 11 months postdiagnosis compared with LO-CRC.”
Dorf, J., Zaręba, K. P., Kamińska, J., Koper‐Lenkiewicz, O. M., Dymicka-Piekarska, V., Pryczynicz, A., Guzińska-Ustymowicz, K., Kędra, B., Matowicka-Karna, J., Żendzian‐Piotrowska, M., et al. (2021) · Cancer Management and Research · doi:10.2147/cmar.s314940 · Cited by 34
“CIN molecular pathway is characterized by the inactivation or deletion of oncogenes and tumour suppressor genes and other mutations (APC, TP53, KRAS, NRAS, SMAD4, PIK3CA, FBXW7, and TCF7L2), whereas defects in the DNA mismatch repair system (MSH2, MLH1, MSH6, MSH3, PMS2, MLH3, and Exo2) are typical for MSI pathway.(7)…”
BackgroundFoppa, C., Tamburello, S., Maroli, A., Carvello, M., Poliani, L., Laghi, L., Malesci, A., Montorsi, M., Perea, J., & Spinelli, A. (2021) · European Journal of Surgical Oncology · doi:10.1016/j.ejso.2021.10.021 · Cited by 31
Ge, H., Yan, Y., Xie, M., Guo, L., & Tang, D. (2019) · International Journal of Surgery · doi:10.1016/j.ijsu.2019.10.021 · Cited by 29
Colorectal Cancer at the Crossroads: The Good, the Bad, and the Future of Platinum-Based Drugs
Kee, J. X., Yau, J. N. N., Muthuramalingam, R. P. K., Wang, X., Chng, W. H., Lopez‐Sanchez, A., Tay, K. K. W., Deng, L., Gibson, D., Bertrand, H. C., et al. (2025) · Chemical Reviews · doi:10.1021/acs.chemrev.5c00041 · Cited by 35
Ottaiano, A., Santorsola, M., Capuozzo, M., Perri, F., Circelli, L., Cascella, M., Ianniello, M., Sabbatino, F., Granata, V., Izzo, F., et al. (2023) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2023.104018 · Cited by 28
Siddiqi, N. N., Stefan, S. S., Jootun, R., Mykoniatis, I., Flashman, K. G., Beable, R., David, G., & Khan, J. S. (2021) · Surgical Endoscopy · doi:10.1007/s00464-020-08194-z · Cited by 28
Patel, A. K., Abhyankar, R., Brais, L. K., Duh, M. S., Barghout, V. E., Huynh, L. Y., Yenikomshian, M. A., Ng, K., & Fuchs, C. S. (2021) · The Oncologist · doi:10.1002/onco.13942 · Cited by 27
Suga, D., Mizutani, H., Fukui, S., Kobayashi, M., Shimada, Y., Nakazawa, Y., Nishiura, Y., Kawasaki, Y., Moritani, I., Yamanaka, Y., et al. (2022) · BMC Gastroenterology · doi:10.1186/s12876-022-02382-y · Cited by 30
Molecular testing for colorectal cancer: Clinical applications
Имянитов, Е. Н., & Kuligina, E. S. (2021) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v13.i10.1288 · Cited by 32
Maksimova, P. E., Golubinskaya, E. P., Seferov, B. D., & Zyablitskaya, E. Y. (2023) · Koloproktologia · doi:10.33878/2073-7556-2023-22-2-160-171 · Cited by 31
Jorgensen, B. G., & Ro, S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23042166 · Cited by 24
“Unfortunately, this reduction in mortality appears to be largely associated with carcinomas found on the left side of the colon as they are easier to observe and remove [18], leaving around 10% of all CRCs undetectable via colonoscopy [19].”
BackgroundSegmental Distribution of Hepatocellular Carcinoma in Cirrhotic Livers
Renzulli, M., Brandi, N., Pecorelli, A., Pastore, L. V., Granito, A., Martinese, G., Tovoli, F., Simonetti, M., Dajti, E., Colecchia, A., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12040834 · Cited by 25
“For example, right-sided colon cancers (proximal to the splenic flexure) and left- sided colon cancers (distal to the splenic flexure) are two distinct diseases with different clinical presentations, treatment responses and survival outcomes [14,21].”
BackgroundRahadiani, N., Habiburrahman, M., Abdullah, M., Jeo, W. S., Stephanie, M., Handjari, D. R., & Krisnuhoni, E. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-060839 · Cited by 25
Bastin, D. J., Montroy, J. R., Kennedy, M. A., Martel, A. B., Shorr, R., Ghiasi, M., Boucher, D. M., Wong, B., Gresham, L. M., Diallo, J., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-29630-9 · Cited by 24
Pre-diagnostic leukocyte mitochondrial DNA copy number and colorectal cancer risk
Yang, K., Li, X., Forman, M. R., Monahan, P. O., Graham, B. H., Joshi, A. D., Song, M., Hang, D., Ogino, S., Giovannucci, E. L., et al. (2019) · Carcinogenesis · doi:10.1093/carcin/bgz159 · Cited by 24
“For example, proximal colon cancers are more likely to be microsatellite instability-high (MSI-high) tumors, while distal colon cancers are more likely to be chromosomal instability-high tumors (42).”
BackgroundWRN-Mutated Colorectal Cancer Is Characterized by a Distinct Genetic Phenotype
Zimmer, K., Puccini, A., Xiu, J., Baca, Y., Spizzo, G., Lenz, H., Battaglin, F., Goldberg, R. M., Grothey, A. F., Shields, A. F., et al. (2020) · Cancers · doi:10.3390/cancers12051319 · Cited by 24
“It has been shown that right-sided CRC is more frequently induced by MSI-H/dMMR and BRAF mutations [16,17], whereas in left-sided CRC, the adenoma-carcinoma sequence is driven by the acquisition of APC, KRAS and TP53 alterations [18,19].”
BackgroundDinami, R., Porru, M., Amoreo, C. A., Sperduti, I., Mottolese, M., Buglioni, S., Marinelli, D., Maugeri‐Saccà, M., Sacconi, A., Blandino, G., et al. (2020) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-020-01612-z · Cited by 27
“Since CRC pathogenesis, drug responsiveness and clinical outcome have been reported to also depend on the anatomical location of the tumor and can differ between right side and left side of the colon [39], we evaluated Fig.”
BackgroundUlanja, M. B., Ntafam, C., Beutler, B. D., Antwi‐Amoabeng, D., Rahman, G. A., Ulanja, R. N., Mabrouk, T., Governor, S., Djankpa, F. T., & Alese, O. B. (2022) · Journal of Surgical Oncology · doi:10.1002/jso.27096 · Cited by 24
“LsCC and RsCC are now considered distinct clinical entities that demonstrate unique molecular characteristics, histology, biomarkers, behavior, and treatment response.(7,8) The incidence of CRC is increasing at an alarming rate among young adults in the United States and worldwide.”
BackgroundTalhouni, S., Fadhil, W., Mongan, N. P., Field, L., Hunter, K. J., Makhsous, S., Maciel-Guerra, A., Kaur, N., Nestarenkaitė, A., Laurinavičius, A., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1057292 · Cited by 24
“Increasing evidence has pointed to the location of the tumour affecting cancer pathology, progression and prognosis (2, 3), and ultimately patient’s response to different cancer treatments (4, 5).”
BackgroundKolisnik, T., Sulit, A. K., Schmeier, S., Frizelle, F., Purcell, R. V., Smith, A. N. H., & Silander, O. (2023) · BMC Cancer · doi:10.1186/s12885-023-10848-9 · Cited by 27
Sex Differences in Colon Cancer: Genomic and Nongenomic Signalling of Oestrogen
Harvey, B. J., & Harvey, H. M. (2023) · Genes · doi:10.3390/genes14122225 · Cited by 25
Cunin, L., Aftab, K., Ibrahim, M., Lango, A., Klimovskij, M., & Harshen, R. (2020) · The Surgeon · doi:10.1016/j.surge.2020.02.003 · Cited by 23
Renzi, G. D., Gaballo, G., Gazzaniga, P., & Nicolazzo, C. (2020) · Oncology · doi:10.1159/000510944 · Cited by 27
Metadata
- Authors
- Baran, B., Mert Ozupek, N., Yerli Tetik, N., Acar, E., Bekcioglu, O., & Baskin, Y.
- Affiliations
- Dokuz Eylül University (TR)
- ORCID
- Acar, Emine
- Venue
- Gastroenterology Research
- Publisher
- Elmer Press, Inc.
- Published
- 2018
- Volume
- 11
- Issue
- 4
- Pages
- 264-273
- ISSN
- 1918-2805 (ISSN-L)
- 1918-2813
- PMC
- PMC6089587
- OpenAlex
- W2887365295
- Cited by
- 553
- References
- 113
- Citations by year
- 2026: 62 · 2025: 59 · 2024: 117 · 2023: 76 · 2022: 66 · 2021: 90 · 2020: 56 · 2019: 25 · 2018: 2
- FWCI
- 4.52
- Type
- journal article
- Language
- en
- Open access
- diamond
- doi.org
- Licence
- cc-by-nc
- Locations
- Gastroenterology Research (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- left-sided colorectal cancer, right-sided colorectal cancer, tumor location, mismatch repair deficiency, chromosomal instability, KRAS mutation, APC mutation, PIK3CA mutation, TP53 mutation, adjuvant chemotherapy, 5-fluorouracil, anti-EGFR therapy, immunotherapy, prognosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.